Hebrew Press Releases Hebrew Press Releases Date Title and Summary Toggle Summary08/19/20 BioLineRx Achieves Enrollment Target in Phase 3 GENESIS Trial for Planned Interim Analysis Toggle Summary08/06/20 BioLineRx Reports Second Quarter 2020 Financial Results and Provides Corporate Update Toggle Summary05/27/20 BioLineRx Announces Publication of Data from Ongoing COMBAT/KEYNOTE-202 Clinical Trial in Nature Medicine Toggle Summary05/20/20 BioLineRx Reports First Quarter 2020 Financial Results and Provides Corporate Update Toggle Summary03/12/20 BioLineRx Reports Year-End 2019 Financial Results and Provides Corporate Update Toggle Summary02/27/20 BioLineRx Announces Notice of Allowance from USPTO for Patent Covering Motixafortide (BL-8040) in Combination with anti-PD-1 for the Treatment of any Type of Cancer Toggle Summary01/22/20 BioLineRx Completes Recruitment in Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients with Second-Line Metastatic Pancreatic Cancer Toggle Summary01/14/20 BioLineRx Receives Orphan Drug Designation for Motixafortide (BL-8040) for the Treatment of Pancreatic Cancer in Europe Toggle Summary12/13/19 BioLineRx Announces Updated Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Patients with Second-Line Stage IV Metastatic Pancreatic Cancer Toggle Summary12/05/19 BioLineRx Announces Preliminary Phase 2a Data from Triple Combination Arm of COMBAT/KEYNOTE-202 Study in Second Line Patients with Metastatic Pancreatic Cancer Toggle Summary11/11/19 BioLineRx Reports Third Quarter 2019 Financial Results and Provides Corporate Update Toggle Summary11/05/19 BioLineRx Announces BL-8040 in Combination with KEYTRUDA Shows Clinical Activity in Heavily Pretreated Metastatic Pancreatic Cancer Patients Toggle Summary11/05/19 BioLineRx Presents Preclinical Data from Triple Combination of BL-8040, Anti PD-1 and Chemotherapy Demonstrating Significant Reduction in Pancreatic Tumor Growth and Favorable Changes in Tumor Microenvironment Toggle Summary09/25/19 BioLineRx Announces Dosing of First Patient in Part 2 of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors Toggle Summary09/03/19 BioLineRx Successfully Completes Dose-Escalation Part of Phase 1/2a Clinical Study for AGI-134, a Novel Immunotherapy for Treatment of Solid Tumors Toggle Summary08/06/19 BioLineRx Reports Second Quarter 2019 Financial Results and Provides Corporate Update Toggle Summary05/14/19 BioLineRx Reports First Quarter 2019 Financial Results and Provides Corporate Update Toggle Summary05/07/19 BioLineRx Announces FDA Approval of IND Application for AGI-134, a Novel Immunotherapy Anti-Cancer Vaccine for Solid Tumors Toggle Summary03/28/19 BioLineRx Reports Year End 2018 Financial Results and Provides Corporate Update Toggle Summary03/27/19 BioLineRx Announces Successful Engraftment Data from Phase 3 GENESIS Trial for BL-8040 in Multiple Myeloma Patients Toggle Summary02/04/19 BioLineRx Receives Orphan Drug Designation from the FDA for its Lead Therapeutic Candidate BL-8040 for the Treatment of Pancreatic Cancer